ClinicalTrials.gg
CompletedNCT02165397Updated Mar 3, 2021Results posted

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

A Phase 3 interventional study of Ibrutinib and Placebo in Waldenström's Macroglobulinemia, sponsored by Pharmacyclics LLC.. Completed at 48 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia — 2 open to participants now, 7 under way, 2 of them phase 3. ibrutinib · Waldenstrom Macroglobulinemia.

Enrollment
4th of 25
181 · median 48
Started
2014
with 2 others
Phase 3
4 of 25
none open now
Registered
7th of 25
by date
Lead sponsor
3 of 25
Pharmacyclics LLC.

Among the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, this one is the 4th largest by enrollment, is one of 3 that started in 2014, is one of 4 in phase 3, and was the 7th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 62 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

2 of the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Waldenstrom Macroglobulinemia studies recruiting now, 44 (92%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination with rituximab in participants with Waldenström's macroglobulinemia (WM).

03

Conditions studied

  • Waldenström's Macroglobulinemia

Keywords

  • Ibrutinib
  • Pharmacyclics
  • PCYC
  • Lymphoma
  • Btk inhibitor
  • WM
  • Rituximab
  • Rituxan
  • Waldenström's
  • Waldenstrom Macroglobulinemia
  • non-Hodgkin lymphoma
  • NHL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Eligibility Criteria for the Randomized Study

Inclusion criteria

Inclusion Criteria:

  • Untreated or previously treated for WM. Previously treated subjects must have either documented disease progression or had no response (stable disease) to the most recent treatment regimen
  • Centrally confirmed clinicopathological diagnosis of WM
  • defined as serum monoclonal immunoglobulin M (IgM) >0.5 g/dL
  • Symptomatic disease meeting at least 1 of the recommendations from the Second International Workshop on Waldenström Macroglobulinemia for requiring treatment
  • Hematology and biochemical values within protocol-defined limits
  • Men and women ≥ 18 years of age
  • (ECOG) performance status of ≤ 2

Exclusion criteria

Exclusion Criteria:

  • Known involvement of the central nervous system by WM
  • Disease that is to the last prior rituximab-containing therapy defined as either

    • Relapse after the last rituximab-containing therapy \< 12 months since last dose of rituximab, OR
    • Failure to achieve at least a minor response (MR) after the last rituximab-containing therapy If the subject meets this exclusion criterion and therefore is excluded from the main randomized study, participation in the non randomized substudy (Arm C) may be considered
  • Rituximab treatment within the last 12 months before the first dose of study drug
  • Known anaphylaxis or (immunoglobulin E) IgE-mediated to murine proteins or to any component of rituximab
  • Prior exposure to ibrutinib or other Bruton's tyrosine kinase (BTK) inhibitors
  • Known bleeding disorders (eg, von Willebrand's disease) or hemophilia
  • History of stroke or intracranial hemorrhage within 12 months prior to enrollment.
  • Any uncontrolled active systemic infection.
  • Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.
  • Currently active, cardiovascular disease
  • Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor

Eligibility Criteria for Open-label Substudy Treatment Arm C

The inclusion/exclusion criteria for the substudy (Arm C) are identical to those described above for the randomized study but, to be eligible, subjects need to be considered refractory to the last prior rituximab-containing therapy defined as either

  • Relapse after the last rituximab-containing therapy \<12 months since last dose of rituximab, OR
  • Failure to achieve at least a MR after the last rituximab-containing therapy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    Randomized Study (Ibrutinib + Rituximab)

    Ibrutinib: 420 mg (3 capsules x 140 mg) orally administered daily beginning from Day 1. Rituximab: 375 mg/m\^2 intravenous (IV) per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.

    Drug: Ibrutinib · Drug: Rituximab

  • Experimental
    Randomized Study (Placebo + Rituximab)

    Placebo: 3 capsules of placebo orally administered daily beginning from Day 1. Rituximab: 375 mg/m\^2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.

    Drug: Placebo · Drug: Rituximab

  • Experimental
    Open-Label Substudy (Ibrutinib)

    Ibrutinib: 420 mg (3 capsules) orally administered daily beginning from Day 1.

    Drug: Ibrutinib

Interventions

  • Participants will receive 420 mg of Ibrutinib orally.

    Also known as: PCI-32765

  • DrugPlacebo

    Participants will receive placebo capsules orally.

  • Participants will receive rituximab 375 mg/m\^2 IV.

    Also known as: Rituxan

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54

    PFS was defined as the time from date randomization to date of first IRC-confirmed disease progression (PD) assessed according to the modified VIth International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria (National Comprehensive Cancer Network \[NCCN\] 2014) or death due to any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. As the median PFS was not reached in the Ibrutinib + Rituximab arm at the time of the analysis, Kaplan Meier landmark estimate of the PFS rate at 54 months (that is, the estimated percentage of participants with PFS at Month 54) is presented.

    Time frame: Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])

Secondary outcomes

  1. Overall Response Rate (ORR) Based on IRC Assessment Up to 3 Years After Last Participant Randomized

    ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), very good partial response (VGPR), or partial response (PR) per the IRC assessment at or prior to initiation of subsequent antineoplastic therapy and confirmed by 2 consecutive assessments. IRC assessment of response was conducted according to the modified VIth IWWM (NCCN 2014) criteria and incorporated assessments from the central radiology review. CR required complete resolution of lymphadenopathy/splenomegaly if present at baseline. VGPR and PR required reduction in lymphadenopathy/splenomegaly if present at baseline.. Kaplan-Meier estimate.

    Time frame: Median time on study: 49.7 months (Ibr+R and Pbo+R) and 57.9 months (Open-Label Ibr)

  2. Time to Next Treatment (TnT) Time From the Date of Randomization to the Start Date of Any Subsequent WM Treatment.

    TTnT was measured from the date of randomization to the start date of any subsequent WM treatment. Participants without subsequent treatment were censored at the date of the last study visit. As the median TTnT was not reached in the Ibrutinib + Rituximab arm and the Open-Label Substudy arm at the time of the analysis, Kaplan Meier landmark estimate of the TTnT rate at 54 months (that is, the estimated percentage of participants not receiving subsequent WM treatment at Month 54) are presented.

    Time frame: Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])

  3. Percentage of Participants With Sustained Hemoglobin (Hgb) Improvement Up to 3 Years After Last Participant Randomized

    Percentage of participants achieving a sustained improvement in Hgb at or prior to initiation of subsequent antineoplastic therapy. Hgb improvement is defined as an increase of ≥ 2 g/dL over baseline regardless of baseline value, or an increase to \>11 g/dL with a ≥0.5 g/dL improvement if baseline is ≤ 11 g/dL. Sustained Hgb improvement is defined as improvement that is sustained continuously for ≥ 56 days (8 weeks) without blood transfusion or growth factors, which includes hemoglobin \> 110 g/L with at least a 5 g/L improvement if baseline ≤110 g/L or increase ≥20 g/L over baseline.

    Time frame: Median time on study: 49.7 months (Ibr+R and Pbo+R) and 57.9 months (Open-Label Ibr)

  4. Percentage of Participants With ≥ 3 Points Increase From Baseline by Week 25 in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Subscale Score

    Percentage of participants with ≥ 3 points increase from baseline by Week 25 in the FACIT-Fatigue subscale score.The FACIT-Fatigue is a 13-item questionnaire that assesses participant reported fatigue and its impact upon daily activities and function over the past 7 days. Each of the 13 items of the FACIT-Fatigue Scale ranges from 0-4, with a range of possible total scores from 0 (extreme fatigue) to 52 (no fatigue). Scores below 30 indicate severe fatigue.

    Time frame: Baseline, 25 weeks

  5. Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 54

    OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive. As the median OS was not reached in any treatment arm at the time of the analysis, Kaplan Meier point estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 54) are presented.

    Time frame: Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])

07

Results

Posted Nov 16, 2020

Participant flow

This study was conducted in 48 sites (10 in the United States, 30 in Europe, 4 in Canada and 4 in Australia).

Participant flow — Overall Study
MilestoneIbrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: Ibrutinib
Started757531
Completed615621
Not completed141910
Withdrew: Death7108
Withdrew: Lost to follow-up130
Withdrew: Withdrawal by subject661
Withdrew: Other, not specified001

Outcome measures

PrimaryProgression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54

PFS was defined as the time from date randomization to date of first IRC-confirmed disease progression (PD) assessed according to the modified VIth International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria (National Comprehensive Cancer Network \[NCCN\] 2014) or death due to any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. As the median PFS was not reached in the Ibrutinib + Rituximab arm at the time of the analysis, Kaplan Meier landmark estimate of the PFS rate at 54 months (that is, the estimated percentage of participants with PFS at Month 54) is presented.

Time frame:
Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])
Reported as:
Number · percentage of participants
Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54
percentage of participantsIbrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: Ibrutinib
Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 5468.0 (54.8 to 78.1)25.3 (15.3 to 36.6)39.7 (22.3 to 56.7)
Statistical analysis
  • Ibrutinib + Rituximab vs Placebo + Rituximab · Log Rank · p = < 0.0001 (The treatment effect was tested with a stratified log rank test.) · Hazard ratio (hr): 0.250 · 95% CI 0.148 to 0.420The hazard ratio and its 95% confidence interval were based on a Cox regression model stratified by the randomization stratification factors.
SecondaryOverall Response Rate (ORR) Based on IRC Assessment Up to 3 Years After Last Participant Randomized

ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), very good partial response (VGPR), or partial response (PR) per the IRC assessment at or prior to initiation of subsequent antineoplastic therapy and confirmed by 2 consecutive assessments. IRC assessment of response was conducted according to the modified VIth IWWM (NCCN 2014) criteria and incorporated assessments from the central radiology review. CR required complete resolution of lymphadenopathy/splenomegaly if present at baseline. VGPR and PR required reduction in lymphadenopathy/splenomegaly if present at baseline.. Kaplan-Meier estimate.

Time frame:
Median time on study: 49.7 months (Ibr+R and Pbo+R) and 57.9 months (Open-Label Ibr)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Based on IRC Assessment Up to 3 Years After Last Participant Randomized
percentage of participantsIbrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: Ibrutinib
Overall Response Rate (ORR) Based on IRC Assessment Up to 3 Years After Last Participant Randomized76.030.777.4
Statistical analysis
  • Ibrutinib + Rituximab vs Placebo + Rituximab · Cochran-Mantel-Haenszel · p = < 0.0001 (Response rate was compared using Cochran-Mantel-Haenszel (CMH) chi-square test.) · Rate ratio: 2.526 · 95% CI 1.753 to 3.639
SecondaryTime to Next Treatment (TnT) Time From the Date of Randomization to the Start Date of Any Subsequent WM Treatment.

TTnT was measured from the date of randomization to the start date of any subsequent WM treatment. Participants without subsequent treatment were censored at the date of the last study visit. As the median TTnT was not reached in the Ibrutinib + Rituximab arm and the Open-Label Substudy arm at the time of the analysis, Kaplan Meier landmark estimate of the TTnT rate at 54 months (that is, the estimated percentage of participants not receiving subsequent WM treatment at Month 54) are presented.

Time frame:
Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])
Reported as:
Number · percentage of participants
Time to Next Treatment (TnT) Time From the Date of Randomization to the Start Date of Any Subsequent WM Treatment.
percentage of participantsIbrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: Ibrutinib
Time to Next Treatment (TnT) Time From the Date of Randomization to the Start Date of Any Subsequent WM Treatment.87.4 (77.2 to 93.3)29.4 (18.2 to 41.6)64.6 (44.1 to 79.2)
Statistical analysis
  • Ibrutinib + Rituximab vs Placebo + Rituximab · Log Rank · p = < 0.0001 (P-value is from a stratified log-rank test.) · Hazard ratio (hr): 0.102 · 95% CI 0.049 to 0.212Hazard ratio is estimated using a stratified Cox regression model.
SecondaryPercentage of Participants With Sustained Hemoglobin (Hgb) Improvement Up to 3 Years After Last Participant Randomized

Percentage of participants achieving a sustained improvement in Hgb at or prior to initiation of subsequent antineoplastic therapy. Hgb improvement is defined as an increase of ≥ 2 g/dL over baseline regardless of baseline value, or an increase to \>11 g/dL with a ≥0.5 g/dL improvement if baseline is ≤ 11 g/dL. Sustained Hgb improvement is defined as improvement that is sustained continuously for ≥ 56 days (8 weeks) without blood transfusion or growth factors, which includes hemoglobin \> 110 g/L with at least a 5 g/L improvement if baseline ≤110 g/L or increase ≥20 g/L over baseline.

Time frame:
Median time on study: 49.7 months (Ibr+R and Pbo+R) and 57.9 months (Open-Label Ibr)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Hemoglobin (Hgb) Improvement Up to 3 Years After Last Participant Randomized
percentage of participantsIbrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: Ibrutinib
Percentage of Participants With Sustained Hemoglobin (Hgb) Improvement Up to 3 Years After Last Participant Randomized77.342.771.0
Statistical analysis
  • Ibrutinib + Rituximab vs Placebo + Rituximab · Chi-squared · p = < 0.0001 · Rate ratio: 1.813 · 95% CI 1.357 to 2.421
SecondaryPercentage of Participants With ≥ 3 Points Increase From Baseline by Week 25 in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Subscale Score

Percentage of participants with ≥ 3 points increase from baseline by Week 25 in the FACIT-Fatigue subscale score.The FACIT-Fatigue is a 13-item questionnaire that assesses participant reported fatigue and its impact upon daily activities and function over the past 7 days. Each of the 13 items of the FACIT-Fatigue Scale ranges from 0-4, with a range of possible total scores from 0 (extreme fatigue) to 52 (no fatigue). Scores below 30 indicate severe fatigue.

Time frame:
Baseline, 25 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 3 Points Increase From Baseline by Week 25 in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Subscale Score
percentage of participantsIbrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: Ibrutinib
Percentage of Participants With ≥ 3 Points Increase From Baseline by Week 25 in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Subscale Score68.054.787.1
Statistical analysis
  • Ibrutinib + Rituximab vs Placebo + Rituximab · Cochran-Mantel-Haenszel · p = 0.1059 (CMH chi squared test) · Rate ratio: 1.238 · 95% CI 0.955 to 1.603
SecondaryOverall Survival (OS) - Kaplan Meier Landmark Estimates at Month 54

OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive. As the median OS was not reached in any treatment arm at the time of the analysis, Kaplan Meier point estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 54) are presented.

Time frame:
Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])
Reported as:
Number · percentage of participants
Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 54
percentage of participantsIbrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: Ibrutinib
Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 5486.4 (73.7 to 93.3)84.2 (71.3 to 91.6)73.4 (53.7 to 85.7)
Statistical analysis
  • Ibrutinib + Rituximab vs Placebo + Rituximab · Log Rank · p = 0.643 (P-value is from unstratified log rank test.) · Hazard ratio (hr): 0.808 · 95% CI 0.328 to 1.99Hazard ratio is estimated using unstratified Cox regression model with treatment as the only covariate.

Adverse events

Collected over From first dose of study drug up to 30 days after the last dose of study drug. Median duration of treatment was 47.7 months for the Ibr+R arm, 15.5 months for the Pbo+R arm, and 40.7 months for the Open-Label Ibr arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib + Rituximab9/75 (12%)40/75 (53.3%)75/75 (100%)
Placebo + Rituximab10/75 (13.3%)25/75 (33.3%)75/75 (100%)
Open-Label Substudy: Ibrutinib8/31 (25.8%)16/31 (51.6%)30/31 (96.8%)
Most frequent serious events
Showing 10 of 117
Most frequent serious events
EventIbrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: Ibrutinib
Atrial fibrillationCardiac disorders8/751/750/31
PneumoniaInfections and infestations8/752/751/31
Infusion related reactionInjury, poisoning and procedural complications0/755/750/31
SyncopeNervous system disorders1/750/752/31
Respiratory tract infectionInfections and infestations4/750/751/31
FallInjury, poisoning and procedural complications3/750/750/31
ArthralgiaMusculoskeletal and connective tissue disorders3/750/750/31
Febrile neutropeniaBlood and lymphatic system disorders0/750/751/31
NeutropeniaBlood and lymphatic system disorders0/750/751/31
ThrombocytopeniaBlood and lymphatic system disorders0/750/751/31
Most frequent other events
Showing 10 of 107
Most frequent other events
EventIbrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: Ibrutinib
Infusion related reactionInjury, poisoning and procedural complications32/7543/750/31
Tumour flareNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/7535/750/31
DiarrhoeaGastrointestinal disorders23/7511/7514/31
PyrexiaGeneral disorders12/7512/7511/31
NeutropeniaBlood and lymphatic system disorders12/757/759/31
Back painMusculoskeletal and connective tissue disorders13/757/759/31
CoughRespiratory, thoracic and mediastinal disorders16/758/759/31
AnaemiaBlood and lymphatic system disorders17/7521/755/31
Increased tendency to bruiseBlood and lymphatic system disorders9/752/758/31
HypertensionVascular disorders18/753/758/31

Baseline characteristics

Age, Customized
Age, Customized(Participants)Ibrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: IbrutinibTotal
< 65 years old28301472
>= 65 years old474517109
Sex: Female, Male
Sex: Female, Male(Participants)Ibrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: IbrutinibTotal
Female30211162
Male455420119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ibrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: IbrutinibTotal
Hispanic or Latino3115
Not Hispanic or Latino727430176
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ibrutinib + RituximabPlacebo + RituximabOpen-Label Substudy: IbrutinibTotal
American Indian or Alaska Native0000
Asian3025
Native Hawaiian or Other Pacific Islander0000
Black or African American1102
White586026144
More than one race0000
Unknown or Not Reported1314330
08

Study locations

48 sites
  • University of California Los Angeles
    Los Angeles, California 90404, United States
  • Stanford Cancer Center
    Palo Alto, California 94305, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Weill Cornell Medical Center
    New York, New York 10065, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37204, United States
  • The Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Concord Repartriation General Hospital
    Concord, New South Wales 2139, Australia
  • Flinders Medical Center
    Bedford Park, South Australia 05042, Australia
  • Peter MacCallum Cancer Center
    Melbourne, Victoria 3000, Australia
  • Cross Cancer Institute
    Edmonton, Alberta T6G1Z2, Canada
  • Queen Elizabeth II Health Sciences Center
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • McGill University Health Center
    Montreal, Quebec H4A3J1, Canada
  • Institut Paoli-Calmettes
    Marseille, Bouches-du-Rhône 13273, France
  • Centre Hospitalier de Saint Brieuc Hopital Yves le Foll
    Saint-Brieuc, Finistère 22027, France
  • Hôtel Dieu
    Nantes, Loire-Atlantique 44093, France
  • CHU de Nancy-Hopital Brabois Adulte
    Vandoeuvre-lès-nancy, Meurthe-et-Moselle 54511, France
  • Hôpital Claude Huriez
    Lille, Nord 59037, France
  • CHU Estaing
    Clermont-Ferrand, Puy-de-Dôme 63000, France
  • Centre Hospitalier Lyon Sud
    Pierre-benite, Rhône 69495, France
  • Hopital Henri Mondor
    Créteil, 94010, France
  • Hôpital Saint Louis
    Paris, 75010, France
  • Groupe Hospitalier Pitié Salpétrière
    Paris, 75651 Cedex 13, France
  • Stauferklinikum Schwäbisch Gmünd
    Mutlangen, Baden-Württemberg 73557, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, Rheinland-Pfalz 55131, Germany
  • Universität Des Saarlandes
    Homburg, Saarland 66421, Germany
  • DIAKO Evangelische Diakonie Krankenhaus gGmbH
    Bremen, 28239, Germany
  • LMU Klinikum der Universität München
    München, 81377, Germany
  • University General Hospital of Patras
    Patras, Achaia 26500, Greece
  • Alexandra Hospital
    Athens, Attiki 11528, Greece
  • University General Hospital of Thessaloniki "AHEPA"
    Thessaloniki, Macedonia 54621, Greece
  • Laiko General Hospital of Athens
    Athens, 11527, Greece
  • Azienda Ospedaliera Città della Salute e della Scienza di Torino
    Torino, Piemonte 10126, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milano, 20162, Italy
  • ASST di Pavia - Fondazione IRCCS Policlinico San Matteo di Pavia
    Pavia, 27100, Italy
  • Azienda Ospedaliero Universitaria Santa Maria della Misericordia di Udine
    Udine, 33100, Italy
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital Universitario de Salamanca
    Salamanca, Castilla Y León 37007, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, 28031, Spain
  • Royal Bournemouth Hospital
    Bournemouth, Dorset BH7 7DW, United Kingdom
09

References and documents

Publications

  • Dimopoulos MA, Tedeschi A, Trotman J, Garcia-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenstrom's Macroglobulinemia. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1. PubMed 29856685 ↗
  • Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, Garcia-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenstrom's Macroglobulinemia. Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10. PubMed 27956157 ↗
  • Buske C, Tedeschi A, Trotman J, Garcia-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. J Clin Oncol. 2022 Jan 1;40(1):52-62. doi: 10.1200/JCO.21.00838. Epub 2021 Oct 4. PubMed 34606378 ↗
  • Trotman J, Buske C, Tedeschi A, Matous JV, MacDonald D, Tam CS, Tournilhac O, Ma S, Treon SP, Oriol A, Ping J, Briso EM, Arango-Hisijara I, Dimopoulos MA. Single-Agent Ibrutinib for Rituximab-Refractory Waldenstrom Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial. Clin Cancer Res. 2021 Nov 1;27(21):5793-5800. doi: 10.1158/1078-0432.CCR-21-1497. Epub 2021 Aug 11. PubMed 34380643 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at the following link.

Data sharing details ↗ · yoda.yale.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in Nov 2019, 64 months.

Results were first posted in Nov 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2014
First posted
Jun 17, 2014
StartActual
Jul 7, 2014
Primary completionActual
Nov 7, 2019
CompletionActual
Nov 7, 2019
Results first posted
Nov 16, 2020
Last update
Mar 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02165397
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Jun 17, 2014
Start date
Jul 7, 2014
Primary completion
Nov 7, 2019
Completion
Nov 7, 2019
Results posted
Nov 16, 2020
Last update
Mar 3, 2021

Study contacts

Bernhard Hauns, MD
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Rituximab

Start the discussion